scPharmaceuticals
SCPH
SCPH was delisted on the 6th of October, 2025.
62 hedge funds and large institutions have $223M invested in scPharmaceuticals in 2023 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 24 increasing their positions, 13 reducing their positions, and 12 closing their positions.
85% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 13
68% more call options, than puts
Call options by funds: $990K | Put options by funds: $591K
47% more capital invested
Capital invested by funds: $152M → $223M (+$71.2M)
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
33% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 12
7% more funds holding
Funds holding: 58 → 62 (+4)
6.5% more ownership
Funds ownership: 62.25% → 68.75% (+6.5%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
+$24.2M |
| 2 |
CAC
Cowen and Company
New York
|
+$20.6M |
| 3 |
JFG
Jefferies Financial Group
New York
|
+$9.64M |
| 4 |
Morgan Stanley
New York
|
+$7.46M |
| 5 |
Millennium Management
New York
|
+$6.07M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$15.4M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$13.3M |
| 3 |
5VM
5AM Venture Management
San Francisco,
California
|
-$11.2M |
| 4 |
PA
Perceptive Advisors
New York
|
-$6.83M |
| 5 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
-$3.48M |
SCPH Hedge Fund Activity: Q1 2023 in Review
62 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in scPharmaceuticals (SCPH) for Q1 2023, worth a combined $223M — up 47% from $152M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new SCPH positions and 12 closed out — a net gain of 4 holders — while 24 added to existing stakes and 13 trimmed.
The largest buyer was RTW Investments, opening a new position worth an estimated $24.2M. The largest seller was Armistice Capital, exiting entirely with an estimated $15.4M sold.
- 62 institutional investors held scPharmaceuticals (SCPH) as of Q1 2023, up from 58 in Q4 2022.
- Funds reported $223M of scPharmaceuticals stock for Q1 2023, up 47% quarter-over-quarter.
- 16 funds opened new scPharmaceuticals positions in Q1 2023 and 12 closed out, a net change of +4 holders.
- The largest scPharmaceuticals buyer in Q1 2023 was RTW Investments, an estimated $24.2M added.
- The largest scPharmaceuticals seller in Q1 2023 was Armistice Capital, an estimated $15.4M sold.
Based on aggregated 13F filings for Q1 2023.